12 completed, 4 unknown, 1 recruiting, 1 terminated. 6 Phase 4, 4 Phase 2, 3 Phase 1, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 3, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Ezetimibe 10mg: new trials by email Literature Review of Ezetimibe 10mg trials Research Report on Ezetimibe 10mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects Obicetrapib 10mg, Ezetimibe 10mg - Healthy Volunteers | Phase 1 | Completed | NewAmsterdam Pharma | 94 | 2024-10-01 | 2024-11-14 |
| Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD） HSK31679 low dose, HSK31679 medium dose, HSK31679 high dose - Hypercholesterolemia | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 210 | 2023-04-26 | 2024-04-09 |
| Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg - Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | Phase 4 | Completed | Yonsei University | 108 | 2022-12-01 | 2025-03-13 |
| Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A Ezetimibe/Atorvastatin 10/5 mg, Atorvastatin 5mg, Ezetimibe 10mg - Hypercholesterolemia, Dyslipidemia | Phase 3 | Completed | Daewon Pharmaceutical Co., Ltd. | 252 | 2022-08-17 | 2023-08-01 |
| Statin and Bone Health Simvastatin 10mg, Ezetimibe 10mg - Diabetes Mellitus, Type 2 | Phase 4 | Unknown | The University of Hong Kong | 240 | 2022-04-13 | 2022-11-28 |
| Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 119 | 2022-03-09 | 2024-07-03 |
| Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial" Ezetimibe 10mg - Acute Myocardial Infarction, Dyslipidemias | Not applicable | Recruiting | Cairo University | 500 | 2021-03-24 | 2026-10-22 |
| Randomized Study of Obicetrapib in Combination With Ezetimibe Obicetrapib 5mg, Ezetimibe 10mg, Placebo - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 112 | 2021-02-23 | 2024-04-24 |
| Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe Ezetimibe 10mg, Placebo - Diabetes Mellitus, Type 2, Diabetic Kidney Disease | Phase 3 | Unknown | Steno Diabetes Center Copenhagen | 60 | 2020-10-01 | 2022-01-18 |
| CHOlesterol Lowering and Residual Risk in Type 2 Diabetes Statin, PCSK9 inhibitor, Ezetimibe 10mg - Type 2 Diabetes | Phase 4 | Completed | NYU Langone Health | 151 | 2020-08-12 | 2024-10-17 |
| Early Alirocumab to Reduce LDL-C in Myocardial Infarction Alirocumab, Atorvastatin 80mg, Ezetimibe 10mg - Myocardial Infarction, Dyslipidemias | Phase 4 | Withdrawn | Imperial College London | 2020-01-01 | 2019-06-13 | |
| Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study Ezetimibe 10mg - Hyperlipidemia; Mixed | Unknown | Misr University for Science and Technology | 3 | 2019-06-01 | 2021-10-15 | |
| Ezetimibe and Orlistat Affect the Intestinal Flora of Hyperlipidemia. Ezetimibe 10mg, Orlistat 120 MG - Hyperlipidemia | Unknown | Fifth Affiliated Hospital of Xinjiang Medical University | 58 | 2019-04-01 | 2019-03-21 | |
| Anti-inflammatory Effects of Simvastatin Simvastatin 40mg, Ezetimibe 10mg - Inflammation, Atherosclerosis | Phase 4 | Terminated | paresh Dandona | 10 | 2017-05-01 | 2024-11-08 |
| Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose, Rosuvastatin 20mg, Ezetimibe 10mg - Healthy | Phase 1 | Completed | Laboratorios Silanes S.A. de C.V. | 36 | 2017-04-30 | 2021-08-24 |
| Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg - Hypercholesterolemia | Phase 2 | Completed | Esperion Therapeutics, Inc. | 63 | 2017-01-19 | 2020-04-03 |
| Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia Rosuvastatin 5mg, DP-R207 5/10mg, Rosuvastatin 10mg - Primary Hypercholesterolemia | Phase 3 | Completed | Alvogen Korea | 379 | 2014-07-01 | 2015-05-15 |
| Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe Rosuvastatin 20mg, Ezetimibe 10mg, Rosuvastatin 20mg + Ezetimibe 10mg - Healthy | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 24 | 2014-06-01 | 2016-10-12 |
| Study of Heart and Renal Protection Simvastatin 20 mg, Ezetimibe 10mg, Placebo - Kidney Disease, Chronic | Phase 4 | Completed | University of Oxford | 9438 | 2003-06-01 | 2012-02-01 |
Dyslipidemias (6) · Hypercholesterolemia (6) · Atherosclerosis (4) · Diabetes Mellitus, Type 2 (3) · Acute Coronary Syndrome (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetic Nephropathies (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type II (1) · Inflammation (1) · Myocardial Infarction (1) · Non-alcoholic Fatty Liver Disease (1) · Renal Insufficiency, Chronic (1)
NewAmsterdam Pharma (3) · Alvogen Korea (1) · Cairo University (1) · Daewon Pharmaceutical Co., Ltd. (1) · Esperion Therapeutics, Inc. (1) · Fifth Affiliated Hospital of Xinjiang Medical University (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Hanmi Pharmaceutical Company Limited (1) · Imperial College London (1) · Laboratorios Silanes S.A. de C.V. (1) · Misr University for Science and Technology (1) · NYU Langone Health (1) · Steno Diabetes Center Copenhagen (1) · The University of Hong Kong (1) · University of Oxford (1)
United States (5) · South Korea (4) · Egypt (2) · United Kingdom (2) · Canada (1) · China (1) · Denmark (1) · Hong Kong (1) · Mexico (1) · Netherlands (1)
Ahmad Samir, MD (1) · Araceli G Medina Nolasco, M.D (1) · Colin Baigent, FRCP, FFPH (1) · Hyeong-Seok Lim, MD PhD (1) · Jeffrey Berger, MD (1) · Kausik Ray, Professor (1) · Marc Ditmarsch (1) · Mark M Feldman (1) · Martin J Landray, PhD, FRCP (1) · Paresh Dandona, MD, PhD (1) · Ron Haberman, MD (1) · Tak Wai David Lui, MD (1) · Yangsoo Jang, Ph.D. (1) · Yongcheol Kim, MD, PhD (1)
PMID 18765432, PMID 21663949, PMID 26385817, PMID 28028192, PMID 28460629, PMID 28780579, PMID 31005271, PMID 31662874, PMID 38018702, PMID 40846146, PMID 41190670, PMID 41560483
2018 (1)